Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combin...
IMMUNE DESIGN CORP COMMON STOCK (IMDZ)
Last immune design corp common stock earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.immunedesign.com/investor-relations
Company Research
Source: GlobeNewswire
Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of survival compared to published data in soft tissue sarcoma patient populationObjective response rate (ORR) for follicular lymphoma patients treated with G100 and pembrolizumab combination therapy increased to 54%, with a 75% ORR in the subset of TLR4-high patients SEATTLE and SOUTH SAN FRANCISCO, March 12, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced updated data from two separate trials evaluating its lead product candidates, CMB305 and G100. CMB305 is a novel prime-boost immunotherapy targeting NY-ESO-1+ cancers, and G100 is a novel synthetic TLR4 agonist for intratumoral immunotherapy. Evidence of clinical benefit continued to mature with both agents, providing not only further support for the advancement of both programs, but also supporting the view that an immunoth
Show less
Read more
Impact Snapshot
Event Time:
IMDZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDZ alerts
High impacting IMMUNE DESIGN CORP COMMON STOCK news events
Weekly update
A roundup of the hottest topics